ACADIA Pharmaceuticals (ACAD) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 792.8% versus a loss of 27.4%. Over five years, SLS leads with a +94.0% price change compared with -8.9% for ACAD. ACADIA Pharmaceuticals is the larger company by market cap ($2.96 billion vs $2.78 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | SLS |
|---|---|---|
| Share price | $17.11 | $13.66 |
| Market cap | $2.96B | $2.78B |
| 1-day change | -2.73% | -8.08% |
| YTD return | -35.94% | +262.33% |
| 1-year return | -27.38% | +792.81% |
| 5-year return | -8.94% | +94.03% |
| P/E ratio (TTM) | 8.07 | — |
| Forward P/E | 15.75 | — |
| EPS (TTM) | $2.12 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.07B | — |
| Revenue growth (YoY) | +11.87% | — |
| Net income (latest FY) | $391.00M | $-26.86M |
| Gross margin | 91.69% | — |
| Operating margin | 9.78% | — |
| Net margin | 36.49% | — |
| 52-week high | $30.96 | $24.89 |
| 52-week low | $15.86 | $1.39 |
| Distance from 52-week high | -44.74% | -45.12% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +77.21% | +137.92% |
| Average volume | 2.18M | 9.64M |
| Shares outstanding | 172.83M | 203.86M |
| Employees | 796 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed ACAD by 820.2 percentage points over the past year.
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
ACAD vs SLS FAQ
Which is bigger, ACADIA Pharmaceuticals or SELLAS Life Sciences Group?
ACADIA Pharmaceuticals (ACAD) is larger, with a market capitalization of $2.96B compared with $2.78B for SELLAS Life Sciences Group (SLS).
Which stock has performed better over the past year, ACAD or SLS?
SLS returned +792.81% over the past 12 months, compared with -27.38% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Are ACADIA Pharmaceuticals and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.